Skip to main content
Clinical Trials/NCT02270580
NCT02270580
Completed
N/A

Patient Navigation to Improve Quality of Life and Screening Practices Among Latino Breast Cancer Survivors

ConditionsBreast Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
The University of Texas Health Science Center at San Antonio
Enrollment
150
Primary Endpoint
Treatment follow-up compliance
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

A randomized controlled trial (RCT) with 2 patient navigator conditions: PN+ and usual PN in which (condition 1) we will evaluate the efficacy of a culturally tailored PN program ("PN+") on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors. In usual PN, participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator.

Detailed Description

This RCT involves a 2 (group) by 2 (time) repeated measures design with experimental condition (specialized PN+cancer survivorship program over 6 months versus PN only (control condition) as the between-groups factor, and time-point (baseline pre-randomization and post-PN at 6 months follow-up) as the within-groups factor. This RCT involves 2 patient navigator conditions: PN+ and usual PN in which (condition 1) we will evaluate the efficacy of a culturally tailored PN program ("PN+") on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors. In usual PN, participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator.

Registry
clinicaltrials.gov
Start Date
June 2012
End Date
July 2014
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • report a primary diagnosis of breast cancer
  • have completed primary treatment within the past 36 months
  • evidence of verbal fluency in English or Spanish
  • self-identify as HL
  • Exclusion Criteria
  • evidence of metastatic disease
  • current severe mental illness such as psychosis
  • substance dependence within the past year
  • active suicidality
  • ongoing neo-adjuvant therapy

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Treatment follow-up compliance

Time Frame: 6 months

Because all of our HL cancer survivors will be recruited within 12-months post-treatment completion for a primary tumor, we will follow ACS guidelines for follow-up care for one- to two-years post-treatment. We will assess via self-report whether the participant missed a scheduled follow-up appointment during the study period. A compliance categorical outcome measure (compliant vs. non-compliant) will be calculated for each participant. Compliance will be defined as attending all scheduled follow-up appointments specific to cancer treatment follow-up during the study period.

Disease-specific quality of life

Time Frame: 6 months

We will administer a cancer-specific FACT version, the FACT-B (breast cancer survivors). It addresses QOL issues that are common sequelae of that certain cancer.

General quality of life

Time Frame: 6 months

The Functional Assessment of Cancer Therapy-General (FACT-G) will be administered to evaluate general domains of QOL. The FACT-G, now in its fourth revision, is one of the most widely used instruments to assess overall adjustment to cancer treatment and survivorship. It is a 27-item self-report questionnaire that takes less than 15 minutes to administer. The FACT-G assesses QOL in four domains of well-being: physical, social/family, emotional and functional well-being. Patients are asked to indicate the extent to which they agree with statements such as "I have pain," "I feel ill," "I get emotional support from my family," "I get support from my friends," "I feel sad," "I feel nervous," "I am sleeping well," and "I am content with the quality of my life right now." The scale is validated for use in many settings with many age groups. We will calculate a composite score for general QOL as well as subscale scores for specific domains of QOL.

Similar Trials

Komen Breast Cancer Survivor Health... | Clinical Trial